bevacizumab for the treatment of patients with ovarian cancer exhibiting poor chemosensitivity
Published 2 years ago • 750 plays • Length 0:47Download video MP4
Download video MP3
Similar videos
-
3:47
gog-0218: which patients with ovarian cancer experience highest benefit from 1l bevacizumab?
-
1:19
real-world use of bevacizumab in patients with breast cancer
-
3:11
the avanova study: niraparib and bevacizumab for ovarian cancer
-
2:50
aurelia: phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer
-
0:34
improving immunotherapy for the treatment of patients with ovarian cancer
-
2:27
the paola-1 study: olaparib and bevacizumab for ovarian cancer
-
1:05
areas of unmet need for patients with ovarian cancer
-
1:10
rebastinib and paclitaxel for advanced/metastatic ovarian cancer
-
7:32
bevacizumab for recurrent ovarian cancer
-
6:01
olaparib and bevacizumab: on the horizon for treating ovarian cancer
-
1:12
dr. herzog on the optimal use of bevacizumab in patients with ovarian cancer
-
6:04
when to add bevacizumab for recurrent ovarian cancer
-
0:45
results for combination bevacizumab plus mirvetuximab soravtansine in ovarian cancer
-
1:05
dr. dowdy on bevacizumab and improvement of pfs in ovarian cancer
-
1:15
safety findings of long-term bevacizumab for patients with ovarian cancer
-
2:56
patient selection for bevacizumab in ovarian cancer
-
8:26
the impact of paola-1 on frontline treatment of ovarian cancer
-
57:43
professor gordon jayson: treating ovarian cancer with anti-angiogenic agents
-
1:36
dr. tew evaluates bevacizumab treatment in ovarian cancer